{{Rsnum
|rsid=3957357
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Orientation=plus
|Orientation=plus
|Chromosome=6
|position=52803889
|Gene=GSTA1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=GSTA1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 16.8 | 49.6 | 33.6
| HCB | 1.5 | 22.6 | 75.9
| JPT | 0.9 | 22.1 | 77.0
| YRI | 8.8 | 46.9 | 44.2
| ASW | 14.0 | 43.9 | 42.1
| CHB | 1.5 | 22.6 | 75.9
| CHD | 0.9 | 12.1 | 86.9
| GIH | 10.0 | 47.0 | 43.0
| LWK | 10.0 | 38.2 | 51.8
| MEX | 6.9 | 39.7 | 53.4
| MKK | 11.0 | 40.0 | 49.0
| TSI | 14.7 | 52.9 | 32.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs3957357
|Name_s=GSTA1:(-69)C>T; GSTA1 -69 C>T polymorphism; GSTA1 (5' flanking) Eam1104I
|Gene_s=GSTAP1, GSTA1
|Feature=
|Evidence=PubMed ID:19786980
|Annotation=In a study of ovarian cancer patients (n=104) receiving a cisplatin-cyclophosphamide regimen, the T/T genotype of GSTA1:(-69)C>T polymorphism was associated with increased overall survival.
|Drugs=cisplatin; cyclophosphamide
|Drug Classes=
|Diseases=Ovarian Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165107197
}}

{{PMID Auto
|PMID=19076156
|Title=Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
|OA=1
}}

{{PMID Auto
|PMID=19448608
|Title=Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3957357
|overall_frequency_n=85
|overall_frequency_d=126
|overall_frequency=0.674603
|n_genomes=46
|n_genomes_annotated=0
|n_haplomes=72
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24423050
|Title=Associations between GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients
|OA=1
}}

{{PMID Auto
|PMID=24919441
|Title=Polymorphisms of NRF2 and NRF2 target genes in urinary bladder cancer patients
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}